vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and TEXAS CAPITAL BANCSHARES INC (TCBI). Click either name above to swap in a different company.
TEXAS CAPITAL BANCSHARES INC is the larger business by last-quarter revenue ($324.0M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 22.8%, a 73.6% gap on every dollar of revenue. On growth, TEXAS CAPITAL BANCSHARES INC posted the faster year-over-year revenue change (15.5% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 10.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
ACAD vs TCBI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $324.0M |
| Net Profit | $273.6M | $73.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 22.8% |
| Revenue YoY | 9.4% | 15.5% |
| Net Profit YoY | 90.3% | 56.8% |
| EPS (diluted) | $1.61 | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $324.0M | ||
| Q4 25 | $284.0M | $327.5M | ||
| Q3 25 | $278.6M | $340.4M | ||
| Q2 25 | $264.6M | $307.5M | ||
| Q1 25 | $244.3M | $280.5M | ||
| Q4 24 | $259.6M | $229.6M | ||
| Q3 24 | $250.4M | $125.3M | ||
| Q2 24 | $242.0M | $267.0M |
| Q1 26 | — | $73.8M | ||
| Q4 25 | $273.6M | $100.7M | ||
| Q3 25 | $71.8M | $105.2M | ||
| Q2 25 | $26.7M | $77.3M | ||
| Q1 25 | $19.0M | $47.0M | ||
| Q4 24 | $143.7M | $71.0M | ||
| Q3 24 | $32.8M | $-61.3M | ||
| Q2 24 | $33.4M | $41.7M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 40.4% | ||
| Q3 25 | 12.8% | 40.5% | ||
| Q2 25 | 12.2% | 33.2% | ||
| Q1 25 | 7.9% | 21.6% | ||
| Q4 24 | 59.1% | 40.7% | ||
| Q3 24 | 12.6% | -63.8% | ||
| Q2 24 | 12.6% | 21.9% |
| Q1 26 | — | 22.8% | ||
| Q4 25 | 96.3% | 30.7% | ||
| Q3 25 | 25.8% | 30.9% | ||
| Q2 25 | 10.1% | 25.2% | ||
| Q1 25 | 7.8% | 16.8% | ||
| Q4 24 | 55.4% | 30.9% | ||
| Q3 24 | 13.1% | -48.9% | ||
| Q2 24 | 13.8% | 15.6% |
| Q1 26 | — | $1.56 | ||
| Q4 25 | $1.61 | $2.11 | ||
| Q3 25 | $0.42 | $2.18 | ||
| Q2 25 | $0.16 | $1.58 | ||
| Q1 25 | $0.11 | $0.92 | ||
| Q4 24 | $0.86 | $1.43 | ||
| Q3 24 | $0.20 | $-1.41 | ||
| Q2 24 | $0.20 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | $878.3M |
| Stockholders' EquityBook value | $1.2B | $3.6B |
| Total Assets | $1.6B | $33.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — |
| Q1 26 | — | $878.3M | ||
| Q4 25 | — | $620.6M | ||
| Q3 25 | — | $620.4M | ||
| Q2 25 | — | $620.3M | ||
| Q1 25 | — | $660.5M | ||
| Q4 24 | — | $660.3M | ||
| Q3 24 | — | $660.2M | ||
| Q2 24 | — | $660.0M |
| Q1 26 | — | $3.6B | ||
| Q4 25 | $1.2B | $3.6B | ||
| Q3 25 | $917.3M | $3.6B | ||
| Q2 25 | $822.4M | $3.5B | ||
| Q1 25 | $765.2M | $3.4B | ||
| Q4 24 | $732.8M | $3.4B | ||
| Q3 24 | $577.2M | $3.4B | ||
| Q2 24 | $516.7M | $3.2B |
| Q1 26 | — | $33.5B | ||
| Q4 25 | $1.6B | $31.5B | ||
| Q3 25 | $1.3B | $32.5B | ||
| Q2 25 | $1.2B | $31.9B | ||
| Q1 25 | $1.1B | $31.4B | ||
| Q4 24 | $1.2B | $30.7B | ||
| Q3 24 | $976.9M | $31.6B | ||
| Q2 24 | $914.1M | $29.9B |
| Q1 26 | — | 0.24× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $360.2M | ||
| Q3 25 | $74.3M | $166.3M | ||
| Q2 25 | $64.0M | $63.0M | ||
| Q1 25 | $20.3M | $368.0K | ||
| Q4 24 | $40.4M | $480.1M | ||
| Q3 24 | $63.2M | $332.8M | ||
| Q2 24 | $25.0M | $33.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $347.6M | ||
| Q3 25 | $73.9M | $161.3M | ||
| Q2 25 | — | $57.5M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $415.2M | ||
| Q3 24 | $63.2M | $317.6M | ||
| Q2 24 | — | $11.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 106.1% | ||
| Q3 25 | 26.5% | 47.4% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | -0.7% | ||
| Q4 24 | — | 180.9% | ||
| Q3 24 | 25.2% | 253.4% | ||
| Q2 24 | — | 4.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.8% | ||
| Q3 25 | 0.1% | 1.5% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 28.2% | ||
| Q3 24 | 0.0% | 12.1% | ||
| Q2 24 | — | 8.3% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 3.58× | ||
| Q3 25 | 1.03× | 1.58× | ||
| Q2 25 | 2.40× | 0.81× | ||
| Q1 25 | 1.07× | 0.01× | ||
| Q4 24 | 0.28× | 6.76× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
TCBI
Segment breakdown not available.
